25 mg/day oral Tirzepatide 15 mg/week Retatrutide 12 mg/week Liraglutide 3.0 mg/day Factor Peak trial weight loss Semaglutide -14.9% at 68 wks (STEP 1) Tirzepatide -22.5% at 72 wks (SURMOUNT-1) Retatrutide -28.7% at 68 wks (TRIUMPH-4) Liraglutide -8% at 56 wks (SCALE) Factor FDA status (June 2026) Semaglutide Approved (T2D, obesity, CVD, MASH, CKD, oral) Tirzepatide Approved (T2D, obesity) Retatrutide Investigational - Phase 3 Liraglutide Approved (Saxenda obesity, Victoza T2D) Factor CV outcomes data Semaglutide Yes - SELECT (20% MACE drop) Tirzepatide SURPASS-CVOT ongoing Retatrutide TRIUMPH-3 ongoing Liraglutide Yes - LEADER (13% MACE drop) These compounds are not interchangeable
About Glutathione
Michael Blmlinger, Flora Hamar, Martin Werle, Florian Fger, Martina Hrouda, Eberhard Ludewig, Christian Huck, Martin Heiss, Lukas Schwarz, Illeum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration, Journal of Controlled Release, 2025, 114164, ISSN 0168-3659,
Managing GLP-1 Side Effects Without Overdosing If you experience bothersome nausea or vomiting within days of a new dose, communicate with your care team before the next injection
